ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• ProQR Therapeutics has a “Moderate Buy” consensus rating from eight analysts, with six buys, one hold, and one sell. The average 12-month price target is $7.50.
• Company insiders purchased 600,000 shares worth approximately $988,500 over the past 90 days, while institutional investors and hedge funds own 32.65% of the stock.
• ProQR reported quarterly EPS of negative $0.09, ahead of the expected negative $0.13, and revenue of $10 million versus the $4.56 million consensus estimate. Shares recently opened at $2.29, with a one-year range of $1.33 to $3.10.

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $7.50.

Several equities analysts have commented on PRQR shares. Chardan Capital dropped their price target on shares of ProQR Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Friday, June 26th. Bank of America initiated coverage on shares of ProQR Therapeutics in a research report on Thursday, August 20th. They set a "buy" rating and a $8.00 price objective for the company. JonesTrading lowered their target price on shares of ProQR Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a report on Friday, June 26th. Wall Street Zen raised shares of ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Saturday, August 15th. Finally, Weiss Ratings upgraded shares of ProQR Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, August 14th.

Insider Activity

In other news, CEO Boer Daniel Anton De bought 150,000 shares of ProQR Therapeutics stock in a transaction dated Thursday, July 9th. The stock was acquired at an average cost of $1.74 per share, with a total value of $261,000.00. Following the acquisition, the chief executive officer owned 300,000 shares of the company's stock, valued at approximately $522,000. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bart Filius bought 150,000 shares of ProQR Therapeutics stock in a transaction dated Friday, July 17th. The stock was purchased at an average cost of $1.72 per share, with a total value of $258,000.00. Following the completion of the acquisition, the director directly owned 300,000 shares in the company, valued at approximately $516,000. The trade was a 100.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 600,000 shares of company stock worth $988,500. Corporate insiders own 8.40% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PRQR. Privium Fund Management B.V. increased its position in ProQR Therapeutics by 7.2% during the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company's stock worth $10,823,000 after buying an additional 359,475 shares during the period. Ikarian Capital LLC boosted its holdings in shares of ProQR Therapeutics by 67.2% in the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company's stock valued at $3,014,000 after acquiring an additional 600,000 shares during the period. Citadel Advisors LLC boosted its holdings in shares of ProQR Therapeutics by 73.2% in the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company's stock valued at $1,399,000 after acquiring an additional 277,749 shares during the period. Walleye Capital LLC grew its position in shares of ProQR Therapeutics by 2.7% during the first quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company's stock worth $984,000 after acquiring an additional 15,744 shares during the last quarter. Finally, Millennium Management LLC grew its position in shares of ProQR Therapeutics by 80.8% during the fourth quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company's stock worth $879,000 after acquiring an additional 194,369 shares during the last quarter. Institutional investors and hedge funds own 32.65% of the company's stock.

ProQR Therapeutics Price Performance

Shares of NASDAQ PRQR opened at $2.29 on Friday. The business has a 50-day moving average of $1.88 and a two-hundred day moving average of $1.71. The company has a market capitalization of $241.27 million, a price-to-earnings ratio of -4.98 and a beta of 0.07. ProQR Therapeutics has a 1 year low of $1.33 and a 1 year high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04. The business had revenue of $10.00 million for the quarter, compared to the consensus estimate of $4.56 million. ProQR Therapeutics had a negative return on equity of 73.83% and a negative net margin of 223.51%. As a group, equities research analysts expect that ProQR Therapeutics will post -0.45 earnings per share for the current year.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company's pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source